Stougaard et al. simulated CVD and ESKD risk in subjects with T1D receiving adjunctive therapy with SGLT2 inhibitors using Steno Type 1 Risk Engines, a predictive model of CVD development in T1D [30]. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.